Healthcare Fraud News Update

Offices of the United States Attorneys   You are subscribed to Healthcare Fraud news updates. This information has recently been updated, and is now available. Caris Life Sciences Pays over $2.8 Million to Settle False Claims Act Allegations from Delay in Submission of Genetic Cancer Screening Tests 06/01/2022 12:00 AM EDT Caris Life Sciences, Inc. (Caris) has agreed to pay $2,886,674.86 to resolve allegations that it violated the False Claims Act in an alleged nationwide scheme to improperly bill Medicare for laboratory tests known as "Caris Molecular Intelligence" and the "ADAPT Biotargeting System." Caris, a molecular science company headquartered in Texas, developed a series of laboratory tests primarily for cancer patients to detect the activity of certain genes within a breast cancer tumor to predict the risk of breast cancer recurrence in patients. These predictive genetic marker tests are used by oncologists and other physicians to assist in determining appropriate treatment options for cancer patients. You have received this e-mail because you have asked to be notified of changes to the Offices of the United States Attorneys website. GovDelivery is providing this service on behalf of the Executive Office for United States Attorneys, Department of Justice, 950 Pennsylvania Ave., NW · Washington, DC 20530 · 202-514-2000 and may not use your subscription information for any other purposes. Manage your Subscriptions | Department of Justice Privacy Policy  | GovDelivery Privacy Policy Follow the Offices of the United States Attorneys on Twitter: @USAttorneys